Drugs / DLBS1033
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01905878 | Jun → Sep 2013 | — | Indonesia University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01694537 | Jul → Oct 2012 | — | Indonesia University | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT07475065 | Mar → May 2026 overdue | diabetes mellitus, diabetic polyneuropathy | Universitas Sebelas Maret | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT02976701 | Nov 2016 → Jan 2023 | ST-elevation myocardial infarction | Dexa Medica Group | Terminated | No outcome recorded |
| Phase 2/3 | NCT02146664 | Nov 2015 → Nov 2017 | acute myocardial infarction | Dexa Medica Group | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02145988 | Jun 2015 → Jun 2018 | diabetes mellitus, peripheral arterial disease | Dexa Medica Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT02133521 | Nov 2014 → Feb 2023 | ischemic stroke | Dexa Medica Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 32 trials | ||||||
| Phase 3 | NCT02362984 | Oct 2014 → Feb 2017 | ischemic stroke | Dexa Medica Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01790997 | May 2012 → Nov 2013 | ischemic stroke | Dexa Medica Group | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07684625 | Mar → Jun 2026 | type 2 diabetes mellitus | Universitas Sebelas Maret | Completed | No outcome recorded |
| Phase 4 | NCT07075289 | Apr → Aug 2024 | benign paroxysmal positional vertigo | Universitas Sebelas Maret | Completed | No outcome recorded |
| Phase 4 | NCT01865474 | May 2013 → Jun 2016 | type 2 diabetes mellitus | Dexa Medica Group | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01378585 | May → Jul 2011 | — | Dexa Medica Group | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DLBS1033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01378585 ↗ |
| Known as | DISOLF | “Participants would get oral lumbrokinase DLBS1033 (490 mg, DISOLF film-coated tablet, Dexa Medica b.i.d.) for a 14-day prospective observation period.” NCT07075289 ↗1“DLBS1033: 490 mg, DISOLF film-coated tablet, Dexa Medica, 3×1 tablet t.i.d. for 4 weeks” NCT07684625 ↗ |
| Known as | Lumbricus Rubellus extract | “Lumbricus Rubellus extract (DLBS1033), produced by PT Dexa Medica through the Dexa Laboratories of Biomolecular Sciences (DLBS) in compliance with Good Manufacturing Practice...” NCT07684625 ↗ |
| Known as | lumbrokinase DLBS1033 | “Participants would get oral lumbrokinase DLBS1033 (490 mg, DISOLF film-coated tablet, Dexa Medica b.i.d.) for a 14-day prospective observation period.” NCT07075289 ↗ |
| Action | Inhibit | “DLBS1033 has demonstrated the ability to reduce TNF-α expression and enhance NGF production in preclinical models.” NCT07475065 ↗ |
| Modality | Protein / enzyme biologic | “DLBS1033 is bioactive protein fraction which extracted from Lumbricus rubellus earthworm.” NCT01694537 ↗ |
| Route | Oral | “safe and promising oral thrombolytic drug” PMID 21403877 ↗ Mar 2011 |
| Target | TNF | “DLBS1033 has demonstrated the ability to reduce TNF-α expression and enhance NGF production in preclinical models.” NCT07475065 ↗ |